в текстеNormalized hemostasis as a new goal in the treatment of hemophilia A in children: the role of efanesoctocog alfa
Pediatric Hematology/Oncology and Immunopathology · 30.06.2026 · 25 (2) · 191-198
DOI: 10.24287/j.1130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Hematology/Oncology and Immunopathology, online erschienen am 30.06.2026. Verfasst von Pavel A. Zharkov. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Hemophilia A remains one of the major challenges in pediatric hematology, because it is during childhood that long-term disease outcomes develop, including the degree of joint damage, the level of physical activity, social adaptation, and quality of life in adulthood. Over the past decades, hemophilia A management has undergone a remarkable transformation, from treating individual bleeding episodes to early prophylaxis, with the aim of preserving joint health and achieving the so-called normalized hemostasis. This review summarizes current knowledge on hemophilic arthropathy, the evolution of the goals of prophylaxis, and the clinical and pharmacokinetic characteristics of efanesoctocog alfa, an ultra-long-acting factor VIII that functions independently of endogenous von Willebrand factor. Special attention is given to pivotal results from the phase III XTEND-Kids and XTEND-1 studies, indirect comparative analyses of standard and extended-half-life products, and non-factor therapy with emicizumab.
Zitieren
APA
Zharkov, P. A. (2026). в текстеNormalized hemostasis as a new goal in the treatment of hemophilia A in children: the role of efanesoctocog alfa. Pediatric Hematology/Oncology and Immunopathology, 25(2), 191-198. https://doi.org/10.24287/j.1130
Vancouver
Zharkov PA. в текстеNormalized hemostasis as a new goal in the treatment of hemophilia A in children: the role of efanesoctocog alfa. Pediatric Hematology/Oncology and Immunopathology. 2026;25(2):191-198. doi:10.24287/j.1130
BibTeX
@article{Zharkov2026,
author = {Zharkov, Pavel A.},
title = {в текстеNormalized hemostasis as a new goal in the treatment of hemophilia A in children: the role of efanesoctocog alfa},
journal = {Pediatric Hematology/Oncology and Immunopathology},
year = {2026},
volume = {25},
number = {2},
pages = {191--198},
doi = {10.24287/j.1130}
}
EUVIMED